KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV)
CUSIP: 483497103
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 50,580,036
- Total 13F shares
- 54,445,883
- Share change
- -445,829
- Total reported value
- $615,513,091
- Put/Call ratio
- 8.9%
- Price per share
- $11.30
- Number of holders
- 138
- Value change
- -$5,352,606
- Number of buys
- 83
- Number of sells
- 48
Quarterly Holders Quick Answers
What is CUSIP 483497103?
CUSIP 483497103 identifies KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 483497103:
Top shareholders of KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VR Adviser, LLC |
13F
|
Company |
13%
|
6,703,985
|
$77,363,987 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Company |
9.9%
|
4,941,798
|
$63,650,358 | $0 | 31 Mar 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
9.7%
|
4,913,012
|
$56,696,158 | — | 31 Mar 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
9.7%
|
4,887,867
|
$56,405,985 | — | 31 Mar 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
9.4%
|
4,751,292
|
$54,829,910 | — | 31 Mar 2025 | |
| Capital World Investors |
13D/G
13F
|
Company |
6.4%
|
3,177,587
|
$40,927,321 | $0 | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
6.2%
|
3,151,735
|
$36,371,022 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.5%
|
2,298,598
|
$26,525,821 | — | 31 Mar 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.4%
|
1,698,984
|
$19,606,275 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
3.2%
|
1,617,469
|
$18,665,592 | — | 31 Mar 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
2.7%
|
1,370,000
|
$15,809,800 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.2%
|
1,093,643
|
$12,620,640 | — | 31 Mar 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
2%
|
1,014,367
|
$11,705,795 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
915,241
|
$10,564,950 | — | 31 Mar 2025 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
1.8%
|
898,190
|
$10,365,113 | — | 31 Mar 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
1.7%
|
868,011
|
$10,355,371 | — | 31 Mar 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
1.5%
|
753,752
|
$8,698,298 | — | 31 Mar 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
1.5%
|
752,359
|
$8,682,223 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.3%
|
645,993
|
$7,455,458 | — | 31 Mar 2025 | |
| EMERALD MUTUAL FUND ADVISERS TRUST |
13F
|
Company |
1.2%
|
608,213
|
$7,018,778 | — | 31 Mar 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
1.2%
|
581,746
|
$6,713,347 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
1%
|
507,703
|
$5,858,893 | — | 31 Mar 2025 | |
| Allostery Investments LP |
13F
|
Company |
0.91%
|
458,302
|
$5,288,805 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.07%
|
37,321
|
$4,934,336 | — | 31 Mar 2025 | |
| Thomas Andrew Crockett |
3/4/5
|
CEO, Director |
—
mixed-class rows
|
322,315
mixed-class rows
|
$4,648,801 | — | 17 Feb 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.8%
|
402,504
|
$4,644,897 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.77%
|
387,562
|
$4,472,465 | — | 31 Mar 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.76%
|
386,837
|
$4,464,099 | — | 31 Mar 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
0.74%
|
375,000
|
$4,327,500 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.67%
|
339,936
|
$3,922,862 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.61%
|
308,247
|
$3,557,170 | — | 31 Mar 2025 | |
| Rosalind Advisors, Inc. |
13F
|
Company |
0.6%
|
303,864
|
$3,506,591 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.55%
|
276,000
|
$3,185,040 | — | 31 Mar 2025 | |
| Saturn V Capital Management LP |
13F
|
Company |
0.5%
|
255,060
|
$2,943,392 | — | 31 Mar 2025 | |
| Walleye Capital LLC |
13F
|
Company |
0.49%
|
249,161
|
$2,875,318 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.44%
|
223,789
|
$2,582,526 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.39%
|
198,205
|
$2,287,286 | — | 31 Mar 2025 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.34%
|
169,692
|
$1,958,246 | — | 31 Mar 2025 | |
| EARNED WEALTH ADVISORS, LLC |
13F
|
Company |
0.01%
|
3,845
|
$1,803,193 | — | 31 Mar 2025 | |
| Nan Fung Group Holdings Ltd |
13F
|
Company |
0.31%
|
154,522
|
$1,783,184 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.29%
|
148,227
|
$1,710,540 | — | 31 Mar 2025 | |
| DIADEMA PARTNERS LP |
13F
|
Company |
0.27%
|
135,509
|
$1,563,774 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.25%
|
126,268
|
$1,457,133 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.22%
|
113,124
|
$1,305,451 | — | 31 Mar 2025 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.22%
|
111,106
|
$1,282,163 | — | 31 Mar 2025 | |
| Edward P. Feener |
3/4/5
|
CHIEF SCIENTIFIC OFFICER |
—
mixed-class rows
|
102,024
mixed-class rows
|
$1,200,262 | — | 17 May 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.2%
|
103,530
|
$1,194,736 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.16%
|
82,896
|
$956,625 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.16%
|
80,965
|
$934,336 | — | 31 Mar 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.14%
|
71,896
|
$829,680 | — | 31 Mar 2025 |
Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q2 2025
As of 30 Jun 2025,
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) was held by
138 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
54,445,883 shares.
The largest 10 holders included
VR ADVISER, LLC, SUVRETTA CAPITAL MANAGEMENT, LLC, TANG CAPITAL MANAGEMENT LLC, Frazier Life Sciences Management, L.P., Vestal Point Capital, LP, Capital World Investors, BlackRock, Inc., VANGUARD GROUP INC, Woodline Partners LP, and SILVERARC CAPITAL MANAGEMENT, LLC.
This page lists
138
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
127
Q2 2025 holders
138
Holder diff
11
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.